What do systematic reviews say?

Periodontal treatment (subgingival instrumentation, with or without antimicrobials/surgery) vs usual care or no treatment

The review found no eligible studies for this question.

• Treatment of periodontitis for glycaemic control in people with diabetes mellitus 2022 · Cochrane All outcomes

  3-4 months
  Included studies did not report data on diabetic complications (some reported medication changes only)
  0 studies
  No studies found

Periodontal treatment (subgingival instrumentation, with or without antimicrobials/surgery) vs usual care or no treatment

• Treatment of periodontitis for glycaemic control in people with diabetes mellitus 2022 · Cochrane All outcomes

  3-4 months
  SoF comment: insufficient evidence to determine whether SRP for glycaemic control is associated with any harms; most studies did not evaluate adverse effects. Where reported (e.g. D'Aiuto 2018) serious adverse events…
  Studies not reported
  GRADE not reported

Periodontal treatment (subgingival instrumentation, with or without antimicrobials/surgery) vs usual care or no treatment

The review found no eligible studies for this question.

• Treatment of periodontitis for glycaemic control in people with diabetes mellitus 2022 · Cochrane All outcomes

  3-4 months
  Included studies did not report cost data. A brief economic commentary drew on four external economic evaluations (Smits 2020, Nasseh 2017, Choi 2020, Soloweij-Wedderburn 2017) suggesting potential cost…
  0 studies
  No studies found

Periodontal treatment (subgingival instrumentation, with or without antimicrobials/surgery) vs usual care or no treatment

Periodontal treatment (subgingival instrumentation, with or without… led to lower clinical attachment level (CAL) compared with no active intervention/usual care; GRADE not reported.

• Treatment of periodontitis for glycaemic control in people with diabetes mellitus 2022 · Cochrane All outcomes

  3-4 months
  MD -0.48 [-0.65, -0.31]
  18 studies
  GRADE not reported

3-month school-based supervised daily tooth-brushing program with fluoridated toothpaste (multilevel: trained school nurses plus parental involvement) vs Pre-intervention

One pre-post study of a school-based supervised tooth-brushing program found visible plaque fell from 76.8% to 36.7% with positive behavior change (narrative synthesis; not GRADE-rated).

• Oral Health of Children and Adolescents in the United Arab Emirates: A Systematic Review of the Past Decade. 2021 All outcomes

  3 months · Dubai, UAE; private and governmental schools
  Al Mashhadani evaluated a 3-month school-based daily tooth-brushing program (1,500 students aged 4-6 in 7 private and governmental schools). The presence of visible plaque decreased from 76.8% to 36.7%…
  1 study · 1500 participants
  GRADE not reported

Daily supervised brushing with fluoridated toothpaste vs Pre-intervention

Visible plaque prevalence decreased from 76.8% before to 36.7% after the intervention.

• Oral Health of Children and Adolescents in the United Arab Emirates: A Systematic Review of the Past Decade. 2021 All outcomes

  Overall
  Visible plaque index (pre-post) 76.8% (pre) to 36.7% (post)
  1 study · 1500 participants
  GRADE not reported

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo)

The review found no eligible studies for this question.

• Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes
  This outcome was not reported in either of the trials.
  0 studies
  No studies found

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo)

The review found no eligible studies for this question.

• Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes
  No randomised or quasi-randomised controlled trials in people with Von Willebrand disease met the inclusion criteria; no eligible VWD trials were identified.
  0 studies
  No studies found

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo)

• Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes
  Only reported in the Walsh (EACA) trial: in none of the 31 included participants was blood transfusion required.
  1 study · 31 participants
  GRADE not reported

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo)

• Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes
  Mean fall in haemoglobin. Forbes (TXA): 1.4 g/100 mL (placebo) vs 0.3 g/100 mL (TXA). Walsh (EACA): 6.3% (placebo, both centres) vs 3.9% and 3.7% (EACA, centres 1 and 2); differences not significant. Reported in…
  2 studies · 59 participants
  GRADE not reported

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo)

The review found no eligible studies for this question.

• Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes
  This outcome was not reported in either of the trials.
  0 studies
  No studies found

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo)

• Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes
  Reported in both trials in different ways. Forbes (TXA): mean units of replacement therapy per root extracted 617 IU (range 0 to 15,800) in 11 placebo participants versus 30 IU and 65 IU per root in 2 TXA participants…
  2 studies · 59 participants
  GRADE not reported

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo)

The review found no eligible studies for this question.

• Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes
  This outcome was not reported in either of the trials.
  0 studies
  No studies found

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo)

• Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes
  Only reported in the Forbes (TXA) trial: over five-day follow-up, mean blood loss per participant 84.1 mL (range 4 to 323) in the placebo group (n=14) versus 61.2 mL (range 1 to 749) in the TXA group (n=14), P = 0.02.
  1 study · 28 participants
  GRADE not reported

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo)

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic… showed no clear difference in side effects or other adverse events compared with placebo, no intervention or usual care (with or without placebo) (low certainty).

• Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes

  Up to 10 days postoperative
  RD 0.034 [-0.32, 0.38]
  2 studies · 59 participants
  Low

Chloral hydrate vs placebo or no intervention

It is very uncertain whether chloral hydrate changes good or better behaviour compared with placebo (including no intervention) (very low certainty).

• Sedation of children undergoing dental treatment 2018 · Cochrane All outcomes
  RR 1.33 [0.80, 2.22]
  1 study · 60 participants
  Very low

Supportive periodontal therapy (SPT) including mechanical debridement vs Monitoring only, or alternative interventions that do not include mechanical debridement

The review found no eligible studies for this question.

• Supportive periodontal therapy (SPT) for maintaining the dentition in adults treated for periodontitis 2018 · Cochrane All outcomes
  no estimate extracted
  0 studies
  No studies found

Meperidine (intramuscular) vs placebo or no intervention

Meperidine (intramuscular) may leads to higher good or better behaviour compared with placebo (including no intervention) (low certainty).

• Sedation of children undergoing dental treatment 2018 · Cochrane All outcomes
  RR 5.33 [1.45, 19.64]
  1 study · 60 participants
  Low

Ketamine/midazolam vs placebo or no intervention

• Sedation of children undergoing dental treatment 2018 · Cochrane All outcomes
  Moreira 2013: 0.5 mg/kg midazolam + 3 mg/kg ketamine produced significantly better behaviour than placebo and oral midazolam (P=0.03); not included in meta-analysis / not GRADE-rated. Narrative.
  1 study
  GRADE not reported

Antifibrinolytic agents (tranexamic acid (TXA) or epsilon aminocaproic acid (EACA)) vs Placebo, no intervention, or usual care

The review found no eligible studies for this question.

• Antifibrinolytic therapy for preventing oral bleeding in people on anticoagulants undergoing minor oral surgery or… 2018 · Cochrane All outcomes
  no estimate extracted
  0 studies
  No studies found